Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
Clinical trial NCT02345226 · COMPLETED
Trial details
- NCT number
- NCT02345226
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-26
- Primary completion
- 2016-06-29
- Enrollment
- 881
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.